Čeština | Dansk | Deutsch | English | Español | Français | Italiano | Nederlands | Norsk | Polski | Português | Pусский | Suomi | Svenska | US
Euro Huntington's disease network [logo]
EHDN2016 DISEASE NETWORK REGISTRY PROJECTS LOGIN
 
 
  
Experimental Rx -
--->Nyheter
[-]Projektet
--->Sponsor
--->[+]Verkställande kommitté
--->[+]Writing Committee Strategic ...
--->[+]Vetenskaplig granskningskom...
--->Centralkoordination
--->Språkkoordination
--->Fellowship Programme
--->[+]Constitution
--->[-]Voting/Nomination
--->[+]Medlemmar
[+]Studiesajter
[-]Arbetsgrupper
--->[-]Advanced HD
--->Dates
--->[+]Meetings
--->[-]Behavioural Phenotype
--->Dates
--->[+]Meetings
--->[+]Psycho appr. & interv. Sub...
--->[+]Biological Modifiers
--->[+]Biomarkers
--->[+]Brain and Tissue Banking
--->[+]Cognitive Phenotype
--->[+]Environmental Modifiers
--->[-]Functional Ability
--->Dates
--->[+]Meetings
--->[+]Genetic Testing
--->[+]Genetic Modifiers
--->[+]Health Economics
--->[+]Imaging
--->[+]Juvenile HD
--->[+]Motor Phenotype
--->[+]Neuroprotective Therapy
--->[-]Physiotherapy
--->Dates
--->[-]Meetings
--->Meeting 2008/05
--->Meeting 2008/09
--->Meeting 2009
--->Meeting 2012
--->Meeting 2014
--->Meeting 2015
--->Meeting 2016
--->Call 2017 Subgroup Guide...
--->[-]Quality of Life
--->[+]Dates
--->[-]Meetings
--->Meeting 2005/03
--->Meeting 2005/09
--->Meeting 2006/07
--->Meeting 2006/12
--->Meeting 2007/09
--->Meeting 2008/08
--->Meeting 2008/09
--->Meeting 2009/11
--->Meeting 2010/05
--->Meeting 2016/09
--->Meeting 2017/07
--->[-]Standard of Care
--->[+]Dates
--->[+]Meetings
--->[+]Dieticians
--->[+]SALT
--->[+]Dental care
--->[+]Occupational
--->[+]Surgical Approaches
--->[+]Symptomatic Research
--->[+]Young Adults
[-]Events
--->[-]EHDN 2016
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Floor plan
--->[+]Overduin Registration
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel booking
--->Social activities
--->Reimbursement
--->[+]Abstract Submission
--->Contacts
--->Documents
--->Feedback
--->EHDN 2014
--->Announcement
--->Introduction
--->Registration
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->CME points
--->Sponsoring
--->Travel Information
--->Hotel Booking
--->Reimbursement
--->Social Activities
--->[+]Abstract Submission
--->Contacts
--->Feedback
--->[-]EHDN 2012
--->Introduction
--->Announcement
--->Programme Fri
--->Programme Sat
--->Programme Sun
--->Additional Meetings
--->Important Dates
--->Registration
--->[+]Travel & Accommodation
--->[+]EHA Registration
--->EHA Programme
--->Reception Dinner
--->About Stockholm
--->[+]Abstract Submission
--->Reimbursement
--->[-]Documents
--->Handouts
--->Presentations
--->[-]Posters
--->Pathogenic mechanisms
--->Animal models
--->Choreatic disorders - no...
--->Genetic modifiers
--->Wet Biomarkers
--->Imaging
--->Clin characteristics
--->Clin char-motor
--->Clin char-cognitive
--->Clin char - behaviour
--->Clin char-other
--->Clinical studies
--->Genetic testing
--->Clinical care
--->Experimental Rx
--->Clinical Rx
--->Non-scientific
--->Contacts
--->Feedback & Evaluation
--->[-]EHDN 2010
--->Introduction
--->Programme I
--->Programme II
--->Additional Meetings
--->Registration
--->EHA Programme
--->[+]EHA Registration
--->Plenary Dinner
--->Social Programme
--->Important Dates
--->[+]Abstract Submission
--->Reimbursement
--->Hotel Booking
--->[+]Travel and Location
--->[+]About Prague
--->Documents
--->Committees
--->Contact
--->Feedback & Evaluation
--->[+]EHDN 2008
--->[+]EHDN 2007
--->[-]EHDN 2006
--->Introduction
--->Final Programme
--->Plenary Dinner
--->Meeting Venue
--->[+]About Blankenberge
--->[+]EHDN 2005
--->[-]EHDN 2004
--->Introduction
--->Final Programme
[-]Kommunikation
--->Kontaktformulär
--->Chattrum
--->Adressregister - offentlig
--->Newsletter
--->Job Offers
datumbeskrivningstorlekförfattare dokument 
04.08.26In vivo efficacy of (CUG)n oligonucleotides to treat HD32 kBanonymousapplication/mswordp02-in-vivo-efficacy-oligonucleotides 
04.08.26Antisense oligonucleotide mediated transcript reduction and modulation – the European approach to develop a therapy for Huntington Disease32 kBanonymousapplication/mswordp01-antisense-oligonucleotide-transcript 
04.08.26Reducing toxic n-terminal Huntingtin fragments in HD using exon skipping32 kBanonymousapplication/mswordp03-exon-skipping 
04.08.26A Huntingtin peptide inhibits polyQ-hHtt associated defects32 kBanonymousapplication/mswordp04-polyq-hhtt-associated-defects 
04.08.26Astrocytes affect neuroprotection: Glatiramer acetate in Huntington`s Disease therapy32 kBanonymousapplication/mswordp07-glatiramer-acetate 
04.08.26Olesoxime improves specific features of the HD pathology32 kBanonymousapplication/mswordp06-olesoxime 
04.08.26Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia – an anti-inflammatory therapy in neurodegenerative disease?!32 kBanonymousapplication/mswordp08-analysis-of-nrf2 

Mapp innehåller 7 dokument.
about us | privacy statement | disclaimer | terms of use